Semaglutide ntabwo igabanya ibiro gusa

Semaglutide ni ibiyobyabwenge bya glucose yatejwe imbere na Novo nodoisk yo kuvura diyabete yo mu bwoko bwa 2. Muri Kamena 2021, FDA yemeje ko Semaglutide yo kwamamaza nk'ibiyobyabwenge by'ibiyobyabwenge (izina ry'ubucuruzi wevgovy). Ibiyobyabwenge ni Glucagon - Peptide ya Glcagon 1 (GLP-1) Kwakira Agoptor Agonist ishobora kwigana ingaruka zayo, kugabanya inzara, bityo bikagabanya imirire na kalorie, bityo bikagabanya indyo, bityo bikagabanya imirire na kalori

Usibye gukoreshwa mu kuvura diyabete n'ubwitonzi, semaglutide na we wasanze arinda ubuzima bw'imitsi, kugabanya ibyago bya kanseri, kandi bifasha kureka kunywa. Byongeye kandi, ubushakashatsi bubiri buherutse bwerekanye ko Semaglutide ishobora no kugabanya ibyago byo kurwanya indwara zimpyisi zidakira n'indwara ya Alzheimer.

Ubushakashatsi bwambere bwerekanye ko gutakaza ibiro bishobora kugabanya ibimenyetso bya pivi osteoarthritis (harimo no gutabara ububabare). Ariko, ingaruka za GLP-1 Kwakira ibiyobyabwenge bigabanijwe ibiro nka semaglutide kubisubizo byaviye osteoarthritis kubantu bafite umubyibuho ukabije ntibize byimazeyo.

Ku ya 30 Ukwakira 2024, abashakashatsi bo muri kaminuza ya Copenhagen na Novo nordisk basohoye impapuro z'ubushakashatsi yitwa abantu bafite umubyibuho ukabije mu kinyamakuru gishya cy'Ubuvuzi (Nejm), ikinyamakuru mpuzamahanga cy'ubuvuzi.

Iyi nyigisho yubuvuzi yerekanaga ko semaglutide ishobora kugabanya cyane kandi ikagabanya cyane ububabare buterwa numubyibuho ukabije (ingaruka zijyanye na ivi rihwanye na opioide), kandi zitezimbere ubushobozi bwabo bwo kwitabira siporo. Nibwo bwa mbere ubwoko bushya bwo kugabanya ibiro, glp-1 yakira Agopor, yemejwe ko yavura rurtritis.